Defining the Role of SGLT2 Inhibitors in Primary Care: Time to Think Differently.
Cardiorenal metabolic continuum
Chronic kidney disease
Diabetes
Heart failure
Primary care
SGLT2 inhibitors
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
01
02
2022
accepted:
23
02
2022
pubmed:
30
3
2022
medline:
30
3
2022
entrez:
29
3
2022
Statut:
ppublish
Résumé
Disease burden in people with diabetes is mainly driven by long-term complications such as cardiovascular disease, heart failure and chronic kidney disease. This is a consequence of the interconnection between the cardiovascular, renal and metabolic systems, through a continuous chain of events referred to as 'the cardiorenal metabolic continuum'. Increasing evidence suggests that sodium-glucose cotransporter 2 inhibitors (SGLT2is) have beneficial effects across all stages of the cardiorenal metabolic continuum, reducing morbidity and mortality in a wide range of individuals, from those with diabetes and multiple risk factors to those with established heart failure and chronic kidney disease, regardless of the presence of diabetes. Despite this robust evidence base, the complexity of label indications and misconceptions concerning potential side effects have resulted in a lack of clear understanding in primary care regarding the implementation of SGLT2is in clinical practice. With this in mind, we provide an overview of the clinical and economic benefits of SGLT2is across the cardiorenal metabolic continuum together with practical considerations in order to help address some of these concerns and clearly define the role of SGLT2is in primary care as a holistic outcomes-driven treatment with the potential to reduce disease burden across the cardiorenal metabolic spectrum.
Identifiants
pubmed: 35349120
doi: 10.1007/s13300-022-01242-y
pii: 10.1007/s13300-022-01242-y
pmc: PMC9076801
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
889-911Informations de copyright
© 2022. The Author(s).
Références
Diabetes Care. 2014 Jul;37(7):1815-23
pubmed: 24929430
Curr Med Res Opin. 2014 Feb;30(2):163-75
pubmed: 24073995
Diabetes Ther. 2018 Oct;9(5):1757-1773
pubmed: 30039249
Lancet Diabetes Endocrinol. 2013 Nov;1(3):208-19
pubmed: 24622369
Diabetes Res Clin Pract. 2014 Mar;103(3):373-81
pubmed: 24529566
Diabetes Care. 2014 Jul;37(7):2055-62
pubmed: 24963113
Nutr Metab Cardiovasc Dis. 2021 Sep 22;31(10):2745-2755
pubmed: 34364771
Diabetes Care. 2015 Mar;38(3):403-11
pubmed: 25468945
Drugs. 2021 Jul;81(11):1243-1255
pubmed: 34160822
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Clin Med (Lond). 2021 May;21(3):204-210
pubmed: 34001571
Curr Opin Nephrol Hypertens. 2015 Jan;24(1):96-103
pubmed: 25470017
Diabetes Obes Metab. 2017 May;19(5):721-728
pubmed: 28116776
Diabetes Obes Metab. 2017 Mar;19(3):329-335
pubmed: 27862902
Diabetes Obes Metab. 2014 Feb;16(2):159-69
pubmed: 23906445
N Engl J Med. 2019 Jan 24;380(4):347-357
pubmed: 30415602
N Engl J Med. 2016 Jul 28;375(4):323-34
pubmed: 27299675
Diabetes Obes Metab. 2012 Oct;14(10):951-9
pubmed: 22776824
N Engl J Med. 2020 Oct 8;383(15):1436-1446
pubmed: 32970396
Circulation. 2021 Jan 26;143(4):310-321
pubmed: 33095032
Diabetes Res Clin Pract. 2017 Aug;130:180-185
pubmed: 28646701
J Clin Endocrinol Metab. 2012 Mar;97(3):1020-31
pubmed: 22238392
Ann Intern Med. 2012 Mar 20;156(6):405-15
pubmed: 22431673
Diabetes Ther. 2018 Oct;9(5):1729-1732
pubmed: 30191537
Aust J Gen Pract. 2021 Apr;50(4):225-230
pubmed: 33786548
J Clin Med. 2021 May 10;10(9):
pubmed: 34068655
Diabetes Ther. 2018 Feb;9(1):253-268
pubmed: 29313282
Diabetes Obes Metab. 2020 Dec;22(12):2364-2374
pubmed: 32744392
Eur Heart J. 2020 Jan 7;41(2):255-323
pubmed: 31497854
Diabetes Obes Metab. 2017 Mar;19(3):348-355
pubmed: 27862830
Curr Opin Cardiol. 2018 Nov;33(6):676-682
pubmed: 30148719
N Engl J Med. 2020 Oct 8;383(15):1413-1424
pubmed: 32865377
Diabetes Care. 2010 Oct;33(10):2217-24
pubmed: 20566676
Drugs. 2022 Feb;82(2):97-108
pubmed: 34932209
Eur J Heart Fail. 2021 Jul;23(7):1217-1225
pubmed: 34051124
Ther Clin Risk Manag. 2021 Aug 12;17:823-830
pubmed: 34408424
Clin Ther. 2015 Aug;37(8):1773-88.e1
pubmed: 26138864
Expert Opin Pharmacother. 2019 Feb;20(2):151-161
pubmed: 30412008
Diabetes Care. 2014;37(3):740-50
pubmed: 24144654
Lancet Diabetes Endocrinol. 2020 Jan;8(1):27-35
pubmed: 31862149
Diabetes Obes Metab. 2018 May;20(5):1111-1120
pubmed: 29266675
Indian J Endocrinol Metab. 2014 Sep;18(5):597-9
pubmed: 25285273
Front Endocrinol (Lausanne). 2017 Jan 24;8:6
pubmed: 28167928
Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700
pubmed: 24948511
BMJ. 2020 Nov 12;371:m4147
pubmed: 33184044
N Engl J Med. 2017 Aug 17;377(7):644-657
pubmed: 28605608
Clin Med (Lond). 2019 Sep;19(5):396-398
pubmed: 31530688
JACC Heart Fail. 2019 Feb;7(2):169-172
pubmed: 30704605
JAMA Netw Open. 2021 Jul 1;4(7):e2114501
pubmed: 34313742
Diab Vasc Dis Res. 2021 Mar-Apr;18(2):14791641211011016
pubmed: 33887983
Diabetes Care. 2011 Sep;34(9):2015-22
pubmed: 21816980
Diabetes Obes Metab. 2011 Oct;13(10):928-38
pubmed: 21672123
World J Diabetes. 2020 Jul 15;11(7):269-279
pubmed: 32843930
Diabetol Metab Syndr. 2019 Sep 26;11:80
pubmed: 31572499
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
J Am Soc Nephrol. 2015 Oct;26(10):2504-11
pubmed: 25733525
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Circulation. 2020 Jan 14;141(2):100-111
pubmed: 31736328
Diabetes. 2021 Jan;70(1):1-16
pubmed: 33106255
Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):73-79
pubmed: 27898586
Diabetes Ther. 2018 Feb;9(1):193-207
pubmed: 29282633
Lancet. 2020 Sep 19;396(10254):819-829
pubmed: 32877652
Nephrol Dial Transplant. 2005 Jun;20(6):1048-56
pubmed: 15814534
PLoS One. 2016 Jul 06;11(7):e0158765
pubmed: 27383068
BMJ Open. 2017 Jan 5;7(1):e013927
pubmed: 28057658
Diabetes Care. 2013 Nov;36(11):3396-404
pubmed: 23963895
Endocrinol Diabetes Metab. 2022 Jan;5(1):e00303
pubmed: 34636161
Diabetes Care. 2012 Jul;35(7):1473-8
pubmed: 22446170
Lancet. 2010 Jun 26;375(9733):2223-33
pubmed: 20609968
Lancet. 2020 Feb 29;395(10225):709-733
pubmed: 32061315
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3077-3087
pubmed: 30835263
Diabetes Obes Metab. 2021 Apr;23(4):1020-1029
pubmed: 33368855
Biomed Res Int. 2014;2014:937398
pubmed: 24959595
Diabetes Obes Metab. 2018 Mar;20(3):530-540
pubmed: 28921862
N Engl J Med. 2021 Jan 14;384(2):117-128
pubmed: 33200892
N Engl J Med. 2021 Oct 14;385(16):1451-1461
pubmed: 34449189
Eur Heart J. 2021 Sep 21;42(36):3599-3726
pubmed: 34447992
Clin Ther. 2016 Dec;38(12):2654-2664.e1
pubmed: 28003053
N Engl J Med. 2020 Oct 8;383(15):1425-1435
pubmed: 32966714
Kidney Int. 2020 Oct;98(4S):S1-S115
pubmed: 32998798
N Engl J Med. 2019 Nov 21;381(21):1995-2008
pubmed: 31535829
Eur J Heart Fail. 2020 Nov;22(11):2147-2156
pubmed: 32749733
N Engl J Med. 2021 Jan 14;384(2):129-139
pubmed: 33200891
Ann Intern Med. 2013 Aug 20;159(4):262-74
pubmed: 24026259
J Manag Care Spec Pharm. 2022 Apr;28(4):415-424
pubmed: 35016548
Diabetes Metab. 2021 Nov;47(6):101285
pubmed: 34597788
Int J Environ Res Public Health. 2019 Aug 17;16(16):
pubmed: 31426529
Curr Heart Fail Rep. 2021 Oct;18(5):315-328
pubmed: 34523061
BMC Med. 2013 Feb 20;11:43
pubmed: 23425012
Medicine (Baltimore). 2016 Nov;95(48):e5473
pubmed: 27902600
Cardiovasc Diabetol. 2021 Feb 5;20(1):36
pubmed: 33546683
Kidney360. 2021 Feb 01;2(4):742-746
pubmed: 35373039
Diabetes Ther. 2014 Jun;5(1):267-83
pubmed: 24920277
Clin J Am Soc Nephrol. 2021 Apr 7;16(4):631-633
pubmed: 33536241
Diabetes Care. 2015 Dec;38(12):2344-53
pubmed: 26604280
Diabetes Obes Metab. 2018 Mar;20(3):520-529
pubmed: 28857451
J Osteopath Med. 2021 Feb 1;121(2):229-239
pubmed: 33567084
Diabetes Ther. 2021 Jan;12(1):313-328
pubmed: 33263893
Circulation. 2019 Oct 29;140(18):1463-1476
pubmed: 31524498
ESC Heart Fail. 2020 Sep 10;:
pubmed: 32909680
JAMA Cardiol. 2021 Aug 1;6(8):926-935
pubmed: 34037681